

DTG Rec'd PCT/PTO 14 FEB 2005

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

.....

Applicants : Kevin Seibert, et al

Int'l Appln.
No. : PCT/GB2003/25679

Int'l Date
Filed : 19 August 2003 (19/08/2003)

Serial No. : (To be assigned) Case No.: 21157YP

Filed : February 14, 2005

For : PROCESS FOR PREPARING
3-CHLOROMETHYL-1,2-4-TRIAZOLIN-5-ONE

.....

Commissioner for Patents
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 2/14/2005
EXPRESS MAIL NO. E298958 7712 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450
MAILED BY AMRELL B. Crowley
DATE 2/14/05

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By


Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: February 14, 2005

21157YP

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

10/524866
 DT05 Rec'd PCT/PTO 14 FEB 2005

Kevin Seibert, et al.

21157YP

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*

Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Journal of the American Chemical Society, 41, 393 (1919) "The Relations Between The Chemical Structures of Carbonyl Derivatives and Their Reactivities Toward Salts of Semicarbazide"

Journal of the American Chemical Society, 52, 1250 (1930) "The Preparation of Semicarbazide"

Tetrahedron Letters, 41 (2000) 8661-8664 "A New Synthesis of 1,2,4-triazolin-5-ones: application to the convergent synthesis of a NK1 antagonist"

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003